Selexipag (NS-304; NS304; ACT-293987; ACT293987; Uptravi) is a novel and potent prodrug of ACT-333679 (MRE-269) acting as non-prostanoid IP receptor agonist and has been approved as a medication for the treatment of pulmonary arterial hypertension. Selexipag and its active metabolite, ACT-333679 (MRE-269), are agonists of the prostacyclin receptor, which can cause vasodilation in the pulmonary circulation.

纯度：≥98%

CAS：475086-01-2